Development of the novel gene-immunotherapy using artificial CTL targeting leukemia stem cells
Project/Area Number |
24390245
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Ehime University |
Principal Investigator |
YASUKAWA Masaki 愛媛大学, 医学(系)研究科(研究院), 教授 (60127917)
|
Co-Investigator(Renkei-kenkyūsha) |
FUJIWARA Hiroshi 愛媛大学, 医学部附属病院, 講師 (20398291)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
Keywords | 白血病 / がん免疫療法 / 細胞傷害性T細胞 / T細胞レセプター / 遺伝子治療 / 細胞障害性T細胞 / CAR-T細胞 / WT1 / 抗体療法 / 白血病幹細胞 / T細胞レセプター / ヒト化マウス / CD16 / hTERT / 免疫療法 |
Outline of Final Research Achievements |
We performed the series of experiment in order to establish the novel gene-immunotherapy targeting leukemia stem cells. WT1-TCR-gene-transduced CTLs exerted cytotoxicity against leukemia cells but not normal cells. It was strongly suggested that leukemia stem cells might be eliminated completely by administration of WT1-TCR gene-modified T cells. WT1-specific and HLA-restricted CTLs could be generated in HLA-TG-NSG mice by transplantation of WT1-TCR gene-transduced human hematopoietic stem cells. CD16-CD3ζ chimeric antigen receptor gene-modified CD8+ T cells showed strong ADCC activity in the presence of anti-CD20 monoclonal antibody targeting malignant lymphoma cells. These data strongly suggest that immunotherapy using gene-modified CTLs can establish the cure of chemotherapy-resistant hematological malignancies.
|
Report
(4 results)
Research Products
(23 results)
-
[Journal Article] Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer2015
Author(s)
Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, Okamoto S, Mineno J, Kuzushima K, Shiku H, and Yasukawa M
-
Journal Title
Leukemia
Volume: in press
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
[Journal Article] Abnormal behaviors and developmental disorder of hippocampus in zinc finger protein 521 (ZFP521) mutant mice.2014
Author(s)
Ohkubo N, Matsubara E, Yamanouchi J, Akazawa R, Aoto M, Suzuki Y, Sakai I, Abe T, Kiyonari H, Matsuda S, Yasukawa M, Mitsuda N.
-
Journal Title
PLoS One
Volume: 9
Issue: 3
Pages: e92848-e92848
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury2014
Author(s)
Asai H, Fujiwara H, Kitazawa S, Kobayashi N, Ochi T, Miyazaki Y, Ochi F, Akatsuka Y, Okamoto S, Mineno J, Kuzushima K, Ikeda H, Shiku H, Yasukawa M
-
Journal Title
J Hematol Oncol.
Volume: 7
Issue: 1
Pages: 3-3
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
[Journal Article] Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.2013
Author(s)
Iwami K, Natsume A, Ohno M, Ikeda H, Mineno J, Nukaya I, Okamoto S, Fujiwara H, Yasukawa M, Shiku H, Wakabayashi T.
-
Journal Title
Neuro Oncol.
Volume: 15
Issue: 6
Pages: 747-758
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Presentation] Concomitant Administration of Gene-Modified T Cells Expressing a Chimeric CD16-CD3ζ Receptor with Mogamulizmab Synergistically Suppresses Adult T Cell Leukemia Cells in Vivo2014
Author(s)
Kazushi Tanimoto , Hiroshi Fujiwara, Hiroki Tanaka, Fumihiro Ochi , Hiroaki Asai, Sachiko Okamoto, JunichiMineno , Kiyotaka Kuzushima, Hiroshi Shiku, John Barrett, and Masaki Yasukawa
Organizer
56th ASH Annual Meeting
Place of Presentation
San Francisco
Year and Date
2014-12-05
Related Report
-
-
-
-
-
-